Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer (original) (raw)
- Clinical Oncology/Epidemiology
- Published: 01 May 1996
Clinical Oncology/Epidemiology
British Journal of Cancer volume 73, pages 1220–1226 (1996)Cite this article
- 286 Accesses
- 101 Citations
- Metrics details
Abstract
The development of familial and sporadic breast cancer is based on genetic alterations of tumour-suppressor genes, for which loss of heterozygosity (LOH) is one mechanism of gene inactivation. To investigate LOH of BRCA1 (17q21) and BRCA2 (13-q12-13) in sporadic breast cancer, polymerase chain reaction (PCR)-based fluorescent DNA technology for detection of microsatellite polymorphisms was applied. A total of 137 breast cancer and 15 benign breast specimens with matched normal tissue were examined. Fluorescent-labelled PCR products were analysed in an automated DNA sequencer (ALFTM Pharmacia). Losses at both loci were correlated with different histological types, age, tumour size, lymph node status, grading and steroid hormone receptor expression, [SHR: oestrogen receptor (ER), progesterone receptor (PgR)]. For BRCA1 (D17S855, THRA1, D17S579) losses could be detected in invasive ductal carcinoma (IDC; n = 108) in 32-38%, invasive lobular carcinoma (ILC; n = 19) in 21-42% depending on the marker applied, but not in benign breast tumours (n = 15). Losses of BRCA1 markers correlated with larger tumour size, higher grade, and PgR expression. For BRCA2 (D13S260, D13S267, D13S171) losses could be detected in 108 IDCs in 30-38%, in 19 ILCs in 17-39% depending on the marker applied, but not in benign breast tumours. Losses of BRCA2 markers correlated only with higher grade. Microsatellite analyses combined with detection of fluorescent-labelled PCR products by an automated laser DNA sequencer can be used for routine determination of LOH. In sporadic breast cancer, LOH of BRCA1 of BRCA2 does not add decisive prognostic value as stated for familial breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Authors and Affiliations
- Department of Gynecology & Obstetrics, Heinrich-Heine-Universität, Düsseldorf, Germany
MW Beckmann
Authors
- MW Beckmann
You can also search for this author inPubMed Google Scholar - F Picard
You can also search for this author inPubMed Google Scholar - HX An
You can also search for this author inPubMed Google Scholar - CR van Roeyen
You can also search for this author inPubMed Google Scholar - SI Dominik
You can also search for this author inPubMed Google Scholar - DS Mosny
You can also search for this author inPubMed Google Scholar - HG Schnürch
You can also search for this author inPubMed Google Scholar - HG Bender
You can also search for this author inPubMed Google Scholar - D Niederacher
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Beckmann, M., Picard, F., An, H. et al. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.Br J Cancer 73, 1220–1226 (1996). https://doi.org/10.1038/bjc.1996.234
- Issue Date: 01 May 1996
- DOI: https://doi.org/10.1038/bjc.1996.234